Kinesin Like Protein KIF11 - Pipeline Review, H2 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
According to the report; Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.
ScopeThe report provides a snapshot of the global therapeutic landscape for Kinesin Like Protein KIF11 The report reviews Kinesin Like Protein KIF11 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in Kinesin Like Protein KIF11 targeted therapeutics and enlists all their major and minor projects The report assesses Kinesin Like Protein KIF11 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type The report summarizes all the dormant and discontinued pipeline projects The report reviews latest news and deals related to Kinesin Like Protein KIF11 targeted therapeutics
Companies Featured4SC AG Alnylam Pharmaceuticals Inc. Kyowa Hakko Kirin Co Ltd. Merck & Co Inc.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/k27c52/kinesin_like?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005349/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Endocrine and Metabolic Disorders Drugs
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/19/2018 07:12 AM/DISC: 09/19/2018 07:12 AM